https://marked.bio/new/index.html Weekly changes across biomarker-selected cancer trials and approvals.en https://marked.bio/new/index.html#w-2026-10-27marked.bio-week-2026-10-27Tue, 27 Oct 2026 12:00:00 +0000<p><b>5 new trials</b> on marked.bio between 20 October 2026 and 27 October 2026.</p><h3>New trials (5)</h3><ul><li><a href="https://clinicaltrials.gov/study/NCT07897188">ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC</a> (Phase 3, Jiangsu Aosaikang Pharmaceutical) <i>EGFR exon 19 deletion / L858R</i></li><li><a href="https://clinicaltrials.gov/study/NCT07886905">Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer</a> (Phase 2, Washington University School of Medicine) <i>BRAF V600E</i></li><li><a href="https://clinicaltrials.gov/study/NCT07897721">A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors</a> (Phase 1, Pfizer) <i>PIK3CA activating mutation</i></li><li><a href="https://clinicaltrials.gov/study/NCT07888647">IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas</a> (Phase 2, German Cancer Research Center) <i>IDH1/2 mutation</i></li><li><a href="https://clinicaltrials.gov/study/NCT07891468">huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers</a> (Phase 1, University of Pennsylvania) <i>ALK fusion</i></li></ul><p>Plus 3 trials open to a broader group (for example any KRAS mutation), listed on <a href="https://marked.bio/new/index.html">What's new</a>.</p>